Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
Currently predicting for Fri, 10 May 2024

Trading levels for EVOK

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 0.575 21.05 %
R2 0.542 14.12 %
R1 0.522 9.84 %
Current price: 0.475
Support S1 0.456 -4.03 %
S2 0.436 -8.31 %
S3 0.403 -15.24 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0.593 24.84 %
R2 0.590 24.21 %
R1 0.540 13.71 %
Current price 0.475
Support S1 0.470 -1.05%
S2 0.458 -3.64%
S3 0.440 -7.37%

EVOK Predictions History

2 years ago
tom_de_laet predicted that EVOK for 2022-04-28 is going

Rank:

2 years ago
AlexVel predicted that EVOK for 2022-04-01 is going $0.503 (9.37%)

2 years ago
barlow660 predicted that EVOK for 2022-04-01 is going

Rank:

2 years ago
ahmednajem96.313079 predicted that EVOK for 2022-04-01 is going $0.520 (5.05%)

Rank:

2 years ago
JS predicted that EVOK for 2021-09-27 is going $1.36 (-0.73%)

2 years ago
Christopher Helgerson predicted that EVOK for 2021-09-27 is going $5.49 (306.67%)

Rank:

2 years ago
JS predicted that EVOK for 2021-09-15 is going $1.06 (-4.50%)

2 years ago
Christopher Helgerson predicted that EVOK for 2021-09-15 is going

Rank:

3 years ago
JS predicted that EVOK for 2020-08-24 is going $4.30 (-4.66%)

3 years ago
iHustle84 predicted that EVOK for 2020-08-24 is going $4.34 (-8.05%)

Click to get the best stock tips daily for free!

About Evoke Pharma

Evoke Pharma Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine ... EVOK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT